Effects of hyperbaric exposure with high oxygen concentration on glucose and insulin levels and skeletal muscle-fiber properties in diabetic rats.
The effects of hyperbaric exposure with high oxygen concentration on glucose and insulin levels and skeletal muscle-fiber properties were investigated in type 2 diabetic Goto-Kakizaki rats. Five-week-old rats were exposed to a hyperbaric environment (1.25 atmospheric pressure) with a high oxygen concentration (36%) for 6 h daily. Glucose and insulin levels and properties including fiber-type distribution, cross-sectional area, and oxidative enzyme activity in the soleus muscle were examined after hyperbaric exposure for 4 weeks. The growth-related increase in glucose level was inhibited by hyperbaric exposure, and insulin also showed lower levels compared with control rats. The percentage of low-oxidative type I fibers in the muscle decreased and high-oxidative type IIA and type IIC fibers, which were not detected in the muscle of control rats, were observed after hyperbaric exposure. The oxidative enzyme activity of type I fibers in the muscle increased after hyperbaric exposure. Hyperbaric exposure with high oxygen concentration might therefore provide a new approach to improve the glucose tolerance, insulin resistance, and altered skeletal muscle metabolism that are caused by diabetes mellitus. Muscle Nerve, 2006.
Yasuda
Koichiro
K
Laboratory of Metabolism, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan.
Adachi
Tetsuya
T
Gu
Ning
N
Matsumoto
Akiko
A
Matsunaga
Tetsuro
T
Tsujimoto
Gozoh
G
Tsuda
Kinsuke
K
Ishihara
Akihiko
A
D052436:Adipose Tissue, White / Q000473:pathology; D000818:Animals; D001786:Blood Glucose / Q000032:analysis* / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000628:therapy*; D004734:Energy Metabolism; D006931:Hyperbaric Oxygenation / Q000379:methods*; D006943:Hyperglycemia / Q000517:prevention & control; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D008297:Male; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D018482:Muscle, Skeletal / Q000201:enzymology* / Q000473:pathology; D009135:Muscular Diseases / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D010085:Oxidative Phosphorylation; D010100:Oxygen / Q000008:administration & dosage / Q000378:metabolism; D010101:Oxygen Consumption; D051381:Rats; D011922:Rats, Mutant Strains; D017208:Rats, Wistar; D013385:Succinate Dehydrogenase / Q000378:metabolism
D001786:Blood Glucose; D007328:Insulin; D013385:Succinate Dehydrogenase; D010100:Oxygen